

ADVIESBEHEER GIMV LIFE SCIENCES NV

Form 4

October 01, 2009

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
GIMV NV

(Last) (First) (Middle)

KAREL OOMSSTRAAT 34

(Street)

ANTWERP, C9 2018

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol

Raptor Pharmaceutical Corp [RPTD]

3. Date of Earliest Transaction
(Month/Day/Year)

09/17/2009

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

____ Director ____ 10% Owner
____ Officer (give title ____X____ Other (specify
below) below)

Former 10% owner

6. Individual or Joint/Group Filing(Check
Applicable Line)

____ Form filed by One Reporting Person
X Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
			Code	V	Amount	(A) or (D)	Price			
Common stock	09/17/2009		S		54,022	D	\$ 0.2703 (1)	1,490,381	I	See footnote (2)
Common stock	09/17/2009		S		6,778	D	\$ 0.2703 (1)	186,998	I	See footnote (3)
Common stock	09/17/2009		S		16,710	D	\$ 0.2703 (1)	460,994	I	See footnote (4)
Common stock	09/18/2009		S		244,699	D	\$ 0.2639	1,245,682	I	See footnote

Common stock	09/18/2009	S	30,702	D	⁽⁵⁾ \$ 0.2639	156,296	I	⁽²⁾ See footnote (3)
Common stock	09/18/2009	S	75,689	D	⁽⁵⁾ \$ 0.2639	385,306	I	⁽⁴⁾ See footnote (4)
Common stock	09/21/2009	S	137,715	D	⁽⁶⁾ \$ 0.2502	1,108,507	I	⁽²⁾ See footnote (2)
Common stock	09/21/2009	S	17,211	D	⁽⁶⁾ \$ 0.2502	139,084	I	⁽³⁾ See footnote (3)
Common stock	09/21/2009	S	42,430	D	⁽⁶⁾ \$ 0.2502	342,876	I	⁽⁴⁾ See footnote (4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Transaction (Instr. 6)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

Former 10% owner

Edgar Filing: ADVIESBEHEER GIMV LIFE SCIENCES NV - Form 4

GIMV NV
KAREL OOMSSTRAAT 34
ANTWERP, C9 2018

ADVIESBEHEER GIMV LIFE SCIENCES NV
KAREL OOMSSTRAAT 34
ANTWERP, C9 2018

Former 10% owner

Biotech Fonds Vlaanderen NV
KAREL OOMSSTRAAT 34
ANTWERP, C9 2018

Former 10% owner

Signatures

Koen Dejonckheere as CEO of Gimv NV

10/01/2009

__Signature of Reporting Person

Date

Patrick Van Beneden as EVP of Gimv NV

10/01/2009

__Signature of Reporting Person

Date

Koen Dejonckheere as director of Adviesbeheer Gimv Life Sciences NV

10/01/2009

__Signature of Reporting Person

Date

Patrick Van Beneden as director of Adviesbeheer Gimv Life Sciences NV

10/01/2009

__Signature of Reporting Person

Date

Koen Dejonckheere as director of Biotech Fonds Vlaanderen NV

10/01/2009

__Signature of Reporting Person

Date

Patrick Van Beneden as director of Biotech Fonds Vlaanderen NV

10/01/2009

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 - (1) Price reflected is the weighted-average sale price for the Torreypines Therapeutics shares sold. The range of sale prices for the transactions reported was \$0.2700 to \$0.2770 per share. The reporting persons undertake to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
 - (2) The reported securities are directly held by Gimv NV. The reporting person on this Form 4 disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest herein.
 - (3) The reported securities are directly held by Adviesbeheer Gimv Life Sciences NV. The reporting person on this Form 4 disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest herein.
 - (4) The reported securities are directly held by Biotech Fonds Vlaanderen NV. The reporting person on this Form 4 disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest herein.
 - (5) Price reflected is the weighted-average sale price for the Torreypines Therapeutics shares sold. The range of sale prices for the transactions reported was \$0.2600 to \$0.2800 per share. The reporting persons undertake to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Edgar Filing: ADVIESBEHEER GIMV LIFE SCIENCES NV - Form 4

- (6) Price reflected is the weighted-average sale price for the Torreypines Therapeutics shares sold. The range of sale prices for the transactions reported was \$0.2500 to \$0.2550 per share. The reporting persons undertake to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Remarks:

This report is filed jointly by Gimv NV, Adviesbeheer Gimv Life Sciences NV, and Biotech Fonds Vlaanderen NV, as member. All reported sold securities are Torreypines Therapeutics Inc. shares that are sold before the merger with Raptor Pharmaceutical.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.